Medicilon Honors Revolution Medicines With Excellence in Client Partnership Award

On October 30, 2026, Medicilon celebrated its long-term partnership with Revolution Medicines, Inc. by presenting the prestigious "Excellence in Client Partnership Award." This award signifies the significant contributions made towards the development of breakthrough therapies, particularly the Pan-KRAS program, which targets previously considered untouchable cancer pathways.

The event was graced by Dr. Yang Liu, the Director of Medicinal Chemistry at Revolution Medicines, and Dr. Kristof Pota, a senior scientist. They visited the Medicilon Research Center in Nanhui, where they engaged with several key figures, including Dr. Maosheng Duan, the President of Medicilon's Pharmaceuticals and Pharmaceutical Research Division, and Dr. Jian Wang, Vice President of Medicilon. This meeting was an opportunity to discuss ongoing projects, data exchange, and set strategic priorities for the upcoming year.

During the ceremony, Dr. Duan praised Revolution Medicines for their innovative advancements in targeting KRAS mutations, which could pave the way for new therapies. He highlighted the recent approval from the FDA for their drug, darakonsib, intended for metastatic pancreatic cancer treatment, as a significant achievement that offers hope to patients facing this daunting disease.

A Model Partnership

This three-year collaboration has fostered a robust R&D framework built on trust and client-centered approaches. Medicilon’s Full-Time Employee (FTE) model has been instrumental in addressing research and development challenges efficiently while remaining focused on delivering high-quality molecules.

The successful partnership reflects a deep-seated commitment to mutual growth and signifies the potential for future breakthroughs. Both teams expressed their desire to maintain this strong collaborative momentum, underpinning their commitment to fighting cancer through innovative drug development.

In the following discussions, Dr. Wang elaborated on the growth of Medicilon’s integrated R&D platform, which spans targeted discovery and the provision of experimental drug solutions. Medicilon operates under stringent international quality standards and holds accreditations that affirm their commitment to excellence, including NMPA, OECD GLP, and FDA GLP.

With advanced capabilities in antibody-drug conjugates (ADC), RNA interference (RNAi), and peptide programs, Medicilon has positioned itself as a leader in providing innovative solutions in pharmaceutical research.

Highlighting New Opportunities

The discussions also revolved around the transfer of information across regions, project management enhancements, and exploring future avenues for collaboration. Both parties are motivated to delve deeper into cross-border R&D efforts, amplifying their operational efficiency and boosting the success rate of new therapies.

As part of the visit, Dr. Liu and Dr. Pota were given a tour of Medicilon's laboratories, which included hands-on insight into their chemical and oligonucleotide labs, as well as the API and preclinical research facilities. This facility tour was instrumental in showcasing the capabilities and infrastructure that drive Medicilon’s research and quality management systems.

In conclusion, the recognition from Medicilon not only celebrates the achievements so far but also lays the groundwork for a more profound and enduring partnership aimed at revolutionizing cancer treatment. The dedication and shared goals of both teams present a beacon of hope in the relentless fight against cancer, illustrating the power of collaboration in research and development.